Influence of С(-344)T variants of the aldosterone synthase CYP11B2 gene on serum aldosterone level and the risk of atrial fibrillation in patients with metabolic syndrome

Background. Metabolic syndrome (MS) with atrial fibrillation (AF) is a significant medical and social problem. AF is a multifactorial disease with a genetic predisposition. Aldosterone contributes to the myocardial fibrosis and remodeling. So, investigation of influence of the aldosterone synthase CYP11B2 gene variants on serum aldosterone level and the risk of AF in patients with MS is of great interest. The purpose of the study was to assess serum aldosterone level as well as the frequency of cases of AF among MS patients with different С(-344)T variants of the CYP11B2 gene (rs1799998). Materials and methods. 201 MS patients (including 99 subjects with AF) and 267 controls were recruited to the study. All participants underwent serum aldosterone level measurement and С(-344)T variants detection with PCR followed by restriction analysis. Results. The frequency of TT genotype in controls was lower than in the MS whole group (p = 0.013) and lower than in the «MS without AF» group (p = 0.005). TT genotype was associated with increased risk of MS [OR = 2,00 (95%CI 1,23-3,26)] as well as with increased risk of «MS without AF» [OR = 1,66 (95%CI 1,11-2,48)]. Aldosterone level in the MS whole group was greater than in controls (p<0.001), and in the «MS with AF» group aldosterone level was greater than in the «MS without AF» group (p = 0.029). In controls, the T allele carriers showed greater aldosterone level compared to the CC genotype carriers (p = 0.015). Conclusion. We showed the association of (-344) Т allele of the aldosterone synthase CYP11B2 gene with the risk of MS, but not with the risk of AF.

метаболический синдром, фибрилляция предсердий, альдостерон, альдостеронсинтаза, CYP11B2, однонуклеотидный полиморфизм, metabolic syndrome, atrial fibrillation, aldosterone, aldosterone synthase, CYP11B2, single nucleotide polymorphism

1. Kirchhof P, Benussi S, Kotecha D et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал 2017; 7(147):7-86.

2. Munoz-Durango N, Vecchiola A, Gonzalez-Gomez LM et al. Modulation of immunity and inflammation by the mineralocorticoid receptor and aldosterone. Biomed Res Int. 2015;2015:652738.

3. Zhang XL, Wu LQ, Liu X et al. Association of angiotensin-converting enzyme gene I/D and CYP11B2 gene -344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation. Exp Ther Med. 2012;4(4):741-747.

4. Fu X, Ma X, Zhong L, Song Z. Relationship between CYP11B2 -344T>C polymorphsim and atrial fibrillation: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2015;16(1):185-8.

5. Lu WH, Bayike M, Liu JW et al. Association between aldosterone synthase (CYP11B2) -344C/T polymorphism and atrial fibrillation among Han and Kazak residents of the Xinjiang region. Int J Clin Exp Med. 2015;8(4):5513-9.

6. Ионин ВА, Соболева АВ, Листопад ОВ и др. Галектин 3 и альдостерон у пациентов с фибрилляцией предсердий и метаболическим синдромом. Российский кардиологический журнал 2015;120(4):79-83.

7. Rajan S, Ramu P, Umamaheswaran G, Adithan C. Association of aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population. Indian J Med Res. 2010;132:379-85.

8. Bellili NM, Foucan L, Fumeron F et al. Associations of the -344 T>C and the 3097 G>A polymorphisms of CYP11B2 gene with hypertension, type 2 diabetes, and metabolic syndrome in a French population. Am J Hypertens. 2010;23(6):660-7.

9. Kim YR, Kim SH, Kang SH et al. Association of CYP11B2 polymorphisms with metabolic syndrome patients. Biomed Rep. 2014;2(5):749-754.

10. Huang H, Darbar D. Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups. Eur Heart J. 2017;38(34):2595-2598.

11. Кускаева АВ, Никулина СЮ, Чернова АА, Аксютина НВ. Генетические предикторы фибрилляции предсердий. Рациональная фармакотерапия в кардиологии 2016;12(3):331-336.

12. Christophersen IE, Ellinor PT. Genetics of atrial fibrillation: from families to genomes. J Hum Genet. 2016;61(1):61-70.

13. Christophersen IE, Rienstra M, Roselli C et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017;49(6):946-952.

14. Pereira PF, Priore SE, Bressan J. Aldosterone: a cardiometabolic risk hormone? Nutr Hosp. 2014;30:1191-1202.

15. Ingelsson E, Pencina MJ, Tofler GH et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992.

16. Bassett MH, Zhang Y, Clyne C et al. Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol. 2002;28(2):125-35.

17. White PC, Rainey WE. Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity. J Clin Endocrinol Metab. 2005;90(2):1252-5.